

AMENDED FORM 9

NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

(or securities convertible or exchangeable into listed securities¹)

Name of Listed Issuer:	Symbol(s):
Entheon Biomedical Corp. (the "Issuer").	ENBI

Date: July 29, 2021 Is this an updating or amending Notice: X Yes No

If yes provide date(s) of prior Notices: June 29, 2021.

Issued and Outstanding Securities of Issuer Prior to Issuance: 54,039,266 common shares of the Issuer (the "Shares").

Pricing

Date of news release announcing proposed issuance: Initial news release issued on June 16, 2021 (the "Initial News Release") and a news release announcing the closing of the Transaction (as defined below) issued on July 29, 2021 (the "Closing News Release") or

Date of confidential request for price protection: N/A.

Closing Market Price on Day Preceding the news release: \$0.42 the day prior to the Initial News Release and \$0.33 the day prior to the Closing News Release or

Day preceding request for price protection: N/A.

Closing

Number of securities to be issued: 5,000,000 Shares.

Issued and outstanding securities following issuance: 59,039,266

Instructions:

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.
5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction

6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 – Distributions*. In addition, the completed form must be delivered to listings@thecse.com with an appendix that includes the information in Table 1B for ALL places.

Part 1. Private Placement N/A.

Table 1A – Summary

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
Total number of purchasers:			
Total dollar value of distribution in all jurisdictions:			

Table 1B – Related Persons

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: _____ .
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. _____ .
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: _____
_____ .
4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities.
5. Description of securities to be issued:
 - (a) Class _____ .
 - (b) Number _____ .
 - (c) Price per security _____ .
 - (d) Voting rights _____ .
6. Provide the following information if warrants, (options) or other convertible securities are to be issued:
 - (a) Number _____ .
 - (b) Number of securities eligible to be purchased on exercise of warrants (or options) _____
_____ .
 - (c) Exercise price _____ .
 - (d) Expiry date _____ .
7. Provide the following information if debt securities are to be issued:
 - (a) Aggregate principal amount _____ .
 - (b) Maturity date _____ .
 - (c) Interest rate _____ .
 - (d) Conversion terms _____ .
 - (e) Default provisions _____ .

8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): ____ .
 - (b) Cash _____ .
 - (c) Securities _____ .
 - (d) Other _____ .
 - (e) Expiry date of any options, warrants etc. _____ .
 - (f) Exercise price of any options, warrants etc. _____ .
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship _____
_____ .
10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).
_____ .
11. State whether the private placement will result in a change of control.
_____ .
12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. _____

_____ .
13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

Part 2. Acquisition

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material:

The Issuer acquired 67,429,417 common shares (“Lobo Shares”) in the capital of Lobo Genetics Inc. (“Lobo”) representing 100% of the issued and outstanding Lobo Shares.

2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material:

The Issuer entered into an amalgamation agreement dated June 15, 2021 (the “Agreement”) with Lobo and 13089363 Canada Inc. (“Subco”), a wholly-owned subsidiary of the Issuer, pursuant to which, by a way of a “three-cornered” amalgamation in accordance with the *Canada Business Corporations Act*, Lobo amalgamated with Subco, whereby the amalgamated company became a wholly-owned subsidiary of the Issuer under the name of “Lobo Genetics Inc.” (the “Transaction”).

3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:

- (a) Total aggregate consideration in Canadian dollars:

A total of \$2,650,000 (5,000,000 Shares at a deemed price of \$0.53 per Share).

- (b) Cash: N/A

- (c) Securities (including options, warrants etc.) and dollar value:

5,000,000 Shares at a deemed price of \$0.53 per Share and 9,603 incentive stock options in the capital of the Issuer (each, an “Option”), with each Option exercisable for one Share at a price of \$6.94 per Option.

- (d) Other: N/A.

- (e) Expiry date of options, warrants, etc. if any: 3,153 Options will expire on July 15, 2025 and 6,460 Options will expire on October 8, 2025.

- (f) Exercise price of options, warrants, etc. if any: See above.
- (g) Work commitments: N/A.
4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc). Arm's-length negotiation.
5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: N/A.
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	Total Securities, Previously Owned, Controlled or Directed by Party	Describe relationship to Issuer ⁽¹⁾
Spartan Bioscience Inc.	1,281,877 Shares ⁽¹⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
John Lem	403,287 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Ajay Krishnan	384,083 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Prakash Gowd	324,550 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

2360203 Ontario Ltd. (Joseph del Moral)	266,369 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Iron and Fuzz Holdings Inc. (Ronan Levy)	171,593 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
CRS Energy Inc. (Hannan Fleiman)	168,036 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
David Ramsaran	183,640 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Avery Haw	172,837 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
DANAD Inc. (Jamie Spiegelman)	123,867 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Eric Ng	104,423 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

Hemanshu Modi	93,620 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
David Bender	73,456 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Snowdevil Capital Inc. (Tobi Lutke)	72,016 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Eric Leong	72,016 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Tariq Zaid	61,880 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Eamon Ryan	52,139 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
2255492 Ontario Inc. (Whit Tucker)	50,411 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Peter Wauthy	33,341 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

Karen Donaldson	30,967 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
9522263 Canada Inc. (Craig Pickering)	30,940 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Fieri Holdings Inc.	30,940 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Niraj Mistry Medicine Professional Corporation	28,806 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Peter Vigile	28,806 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Ramen Ventures Limited Partnership	28,806 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Lily Lem	22,565 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Ken Lem	21,125 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

The AKRO Hughes Family Trust	19,804 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Dr. Sammy Vaidyanathan Medicine Professional Corp.	17,766 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Pasquale Santini	17,046 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
1384092 Ontario Inc. (Doug Leyland)	16,040 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
EBUD Holdings Inc.	16,040 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Bronyk Holdings Ltd.	15,873 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Sarah Zaid	15,470 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Daniel Wong IT Solutions Inc.	13,878 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

B.C. Bockstael Holdings Inc.	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Camille Lem	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Giacomo Armiento	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Kavi Patel	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Laurence Bradley	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Marjorie Medley	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Mohamed Zaid	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

North Bud Capital Holdings Ltd.	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Patricia Billard	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Patricia Doolan	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Ross Bradley	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Ryan Brown	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Sandra Marie Beneteau	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Second Beach - Vaive Family Trust	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

The Finkelstein (2036) Family Trust	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
The Segal 2037 Family Trust	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Thom Bennett	14,403 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Paul Gibbons	13,445 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Garry Foster	12,963 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
George Choma	12,963 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Bernard Von Teichman	12,376 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Jonathan Chu	11,645 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

John Zamparo	11,587 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Ali Qureshi	10,802 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Jasbir Sunner	9,902 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Sohail Sunner	9,902 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Naoko Haruyama	8,642 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Maxwell Mausner	7,987 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
2088845 Ontario Inc. (Philip Rimer)	7,202 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

Andre Audet	7,202 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Aydin Mirzaee (2013) Family Trust	7,202 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
George Polyzois	7,202 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Jerry Ng Wong Hing	7,202 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Karson Holdings Inc.	7,202 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Philip Downey	7,202 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Sasha Sadr	7,202 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Eugene Mark Bender	5,953 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

George Veitch	6,481 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
993690 Ontario Ltd. (Dave Ramey)	5,761 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Ardalan Akbari	5,761 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Deepak Shah	5,761 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Joseph Raymond	5,761 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Thomas Hugh Percival	5,761 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Tom Gougeon	5,761 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

Lawrence Kelly	5,041 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Alan Shayanpour	4,801 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Sid Mokhtari	4,321 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Amber Foucault	3,385 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Anthony Lipkin	3,349 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Paul Crowe	3,349 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Catherine Leyland	3,208 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

Andre Lalonde	3,094 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Alex McDowell	2,881 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Angelo Gasparotto	2,881 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Dan Warren	2,881 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Peter Giroux	2,881 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Solon Angel	2,881 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Stavro Stathonikos	2,881 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

Steven Bernstein	2,401 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
David C. Provan Medicine Professional Corporation	2,401 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Meera Jayarajan Medicine Professional Corporation	2,401 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Brian McNally Holdings, LLC	2,160 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
DnA Snyder LLC	2,160 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
MarqSci LLC	2,160 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Rozhan Makhdoomi	2,160 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

Samantha Gordashko	2,160 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Stephen Halman Medicine Prof. Corp.	1,921 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
2641388 Ontario Corporation (Ahmed Mian)	1,920 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Adrian Carpenter	1,547 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Reginald Peters	1,547 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
6080294 Canada Inc. (JS Cournoyer)	1,440 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Adam Milito	1,440 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length

FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

Eric Foster	1,440 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
William Ormund Murphy	1,440 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Peter Ramey	634 Shares (2)	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Carl Clarke Bond	480 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Chris Mayes	360 Shares ⁽²⁾	\$0.53	N/A	Section 2.11 of NI 45-106	Nil	Arm's Length
Daniel Skilleter	3,143 Replacement Options	\$0.53	\$6.94	Section 2.11 of NI 45-106	Nil	Arm's Length
Michael Wiles	6,460 Replacement Options	\$0.53	\$6.94	Section 2.11 of NI 45-106	Nil	Arm's Length

(1) Indicate if Related Person

(2) Shares subject to contractual restrictions over a 24 month period, with 25% released 6 months from the closing date of the Transaction, and 25% every 6 months thereafter.

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF
LISTED SECURITIES**

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: The Issuer inspected Lobo's central securities register and completed customary due diligence for a transaction of this nature.
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
 - (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): N/A.
 - (b) Cash N/A .
 - (c) Securities N/A.
 - (e) Expiry date of any options, warrants etc. N/A.
 - (f) Exercise price of any options, warrants etc. N/A .
9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. N/A.
10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. N/A.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. the Issuer has obtained the express written consent of each applicable individual to:
 - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
 - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated July 29, 2021

Timothy Ko

Name of Director or Senior Officer

Signature

President, CEO and Director

Official Capacity

Appendix A

PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, “CSE or the “Exchange”) collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

-
- To determine whether an individual is suitable to be associated with a Listed Issuer;
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange’s obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9th Floor, Toronto, ON, M5J 2W4.